(ENTA)—ABBV reports $919M of 1Q18 HCV sales—($343M US; $576M ex-US): https://finance.yahoo.com/news/abbvie-reports-first-quarter-2018-114700801.html Clearly, ABBV’s prior 2018 full-year HCV sales guidance of $2.5B was a lowball figure, as mentioned in the second bullet point in #msg-138017796.